Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated (ACT), which was renamed to Ocata Therapeutics in November 2014. In February 2016 Ocata acquired by Astellas for $379 million. which was finally completed in February 2016.
Advanced Cell Technology was formed in 1994 and was led from 2005 to late 2010 by William M. Caldwell IV, Chairman and Chief Executive Officer. Upon Mr. Caldwell's death on December 13, 2010, Gary Rabin, a member of ACT's board of directors with experience in investment and capital raising, assumed the role of Chairman and CEO.
In November 2010 the FDA allowed Ocata to begin a Phase I/II human clinical trial to use its retinal pigment epithelium cell therapy to treat Stargardt disease, a form of inherited juvenile macular degeneration.
Robert Lanza (born 11 February 1956) is an American medical doctor, scientist and philosopher. He is currently Head of Astellas Global Regenerative Medicine, and is Chief Scientific Officer of the Astellas Institute for Regenerative Medicine and Adjunct Professor at Wake Forest University School of Medicine.
This page is based on a Wikipedia article written by authors
Text is available under the CC BY-SA 3.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.